Read your
family history
at the gene level
Our hereditary cancer panel sequences 60+ genes associated with inherited cancer risk — including BRCA1, BRCA2, and the Lynch syndrome genes — using NCCN-aligned gene selection and ACMG variant classification.
Selected Genes On Panel · Grouped By Syndrome
Personal and family criteria
The following are commonly used NCCN criteria. If any apply to you or a first- or second-degree relative, hereditary cancer testing may be appropriate.
Breast cancer diagnosed at age 50 or younger
Triple-negative breast cancer at any age
Ovarian, fallopian tube, or primary peritoneal cancer at any age
Pancreatic cancer at any age
Metastatic prostate cancer at any age
Colorectal or endometrial cancer before age 50
Two or more close relatives with related cancers
Ashkenazi Jewish ancestry with personal or family breast/ovarian cancer
A known pathogenic variant in the family
Multiple primary cancers in one individual
How an inherited variant moves through a family
Most hereditary cancer syndromes follow an autosomal dominant pattern: a single copy of an altered gene confers risk, and each child of a carrier has a 50% chance of inheriting it.
Selected genes and primary risks
A subset of the 60+ genes covered, organized by primary cancer association.
| Gene | Primary cancers | Inheritance | Management |
|---|---|---|---|
| BRCA1 | Breast, ovarian, prostate, pancreatic | Autosomal dominant | Enhanced screening, risk-reducing surgery |
| BRCA2 | Breast, ovarian, prostate, pancreatic, melanoma | Autosomal dominant | Enhanced screening, PARP inhibitor eligibility |
| PALB2 | Breast, pancreatic | Autosomal dominant | Enhanced breast screening |
| MLH1, MSH2, MSH6, PMS2 | Colorectal, endometrial, gastric, ovarian (Lynch) | Autosomal dominant | Colonoscopy, gynecologic surveillance |
| APC | Colorectal (FAP) | Autosomal dominant | Colectomy by guideline |
| CDH1 | Diffuse gastric, lobular breast | Autosomal dominant | Prophylactic gastrectomy considered |
| TP53 | Sarcoma, breast, brain, adrenocortical (Li-Fraumeni) | Autosomal dominant | Whole-body MRI surveillance |
| PTEN | Breast, thyroid, endometrial (Cowden) | Autosomal dominant | Multi-organ surveillance |
Every result reviewed with a counselor
Hereditary cancer testing is a clinical decision, not a consumer purchase. Pre-test and post-test counseling are part of every order.
Family history review
Three-generation pedigree built with your provider. Indications confirmed against NCCN criteria.
Sample & sequencing
Blood or saliva. Hybrid-capture NGS plus CNV analysis. ACMG variant classification.
Result & cascade
Result discussed with a counselor. Cascade testing recommended for at-risk relatives if a pathogenic variant is found.
Discuss hereditary risk with our team
Our genetic counselors review every case before sample collection. Bring your family history; we'll handle the rest.